Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762.
The bromodomain and extraterminal (BET) protein BRD2-4 inhibitors hold therapeutic promise in preclinical models of hematologic malignancies. However, translation of these data to molecules suitable for clinical development has yet to be accomplished. Herein we expand the mechanistic understanding o...
Main Authors: | Chaidos, A, Caputo, V, Gouvedenou, K, Liu, B, Marigo, I, Chaudhry, M, Rotolo, A, Tough, D, Smithers, N, Bassil, A, Chapman, t, Harker, N, Barbash, O, Tummino, P, Al-Mahdi, N, Haynes, A, Cutler, L, Le, B, Rahemtulla, A, Roberts, I, Kleijnen, M, Witherington, J, Parr, N, Prinjha, R, Karadimitris, A |
---|---|
Format: | Journal article |
Language: | English |
Published: |
American Society of Hematology
2014
|
Similar Items
-
Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010) -
Selective inhibition of BET bromodomains.
by: Filippakopoulos, P, et al.
Published: (2010) -
Developing chemical probes for the BET bromodomains
by: Hewings, D, et al.
Published: (2012) -
Chemical probes for bromodomains outside the BET family
by: Brennan, P, et al.
Published: (2013) -
Bromodomain Blockade for Intimal Hyperplasia — A Good BET?
by: Allison C. Ostriker, et al.
Published: (2015-11-01)